Innovative PartnershipsKazia announced a new agreement with QIMR Berghofer to license a novel PD-L1 degrader program for development and commercialization, potentially making it a first mover in this new space.
Positive Clinical DataPaxalisib has shown an overall survival benefit in unmethylated GBM patients of approximately 15 months compared to 12 months with standard-of-care.
Regulatory SupportThe FDA appears supportive of developing therapies targeting high unmet needs with small patient populations, which may be a tailwind for paxalisib.